Skip to main content

Table 2 Association of 38-gene HGF signature with breast cancer clinical and genomic subtypes and risk of recurrence (ROR) genomic score

From: Hepatocyte growth factor pathway expression in breast cancer by race and subtype

  HGF negative, N (%) HGF positive, N (%) Multivariable RFDa (95% CI)
Total (N) 1329 (68%) 628 (32%)  
IHC-based    
 HR−/HER2+ 62 (57%) 46 (43%) 29.42% (19.91, 38.93)
 TNBC 86 (18%) 391 (82%) 69.04% (64.95, 73.14)
 HR+/HER2− 1053 (89%) 125 (11%) Referent
 TNBC 86 (18%) 391 (82%) 65.85%. (61.71, 69.98)
 Non-TNBC 1115 (87%) 171 (13%) Referent
RNA-based-PAM50   
 Luminal B 288 (94%) 19 (6%) 1.31% (− 1.51, 4.12)
 HER2-enriched 122 (68%) 58 (32%) 27.29% (20.32, 34.27)
 Basal-like 45 (8%) 493 (92%) 86.64% (83.73, 89.55)
 Luminal A 820 (96%) 31 (4%) Referent
 Basal 45 (8%) 493 (92%) 81.84% (78.84, 84.83)
 Non-basal 1230 (92%) 108 (8%) Referent
 High ROR-PT 145 (29%) 352 (71%) 48.20% (43.42, 52.99)
 Low/medium ROR-PT 1133 (81%) 259 (19%) Referent
  1. aRelative frequency differences (RFDs) adjusted for age and race
  2. IHC, immunohistochemistry; ROR-PT, risk of recurrence score incorporating subtype, proliferation, and tumor size